Integra LifeSciences receives FDA clearance for CUSA Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries and other medical applications.
Quiver AI Summary
Integra LifeSciences Holdings Corporation has received FDA 510(k) clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System, allowing its use in cardiac surgeries, particularly for debriding unwanted tissue during valve replacements and repairs. This device is also suitable for a variety of other surgical procedures, including neurosurgery and orthopedic operations, making it versatile for both soft and hard tissue applications. Mike McBreen, an executive at Integra, highlighted this clearance as a significant expansion of the system's capabilities, enhancing the company's ability to provide advanced surgical solutions. Integra will showcase the CUSA Clarity System at the American Association for Thoracic Surgeon Mitral Valve Conclave in New York City on December 11-12, 2025.
Potential Positives
- FDA 510(k) clearance for the CUSA® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries enhances the company's product offerings and showcases its commitment to innovation in medical technology.
- This clearance allows for the use of the CUSA Clarity in both cardiac surgeries and a variety of other surgical procedures, indicating a broad application and potential market growth.
- The announcement emphasizes Integra LifeSciences' position as a leader in the industry, strengthening its reputation and credibility among healthcare professionals.
- The company plans to showcase the CUSA Clarity at a prominent medical conference, which could lead to increased visibility and interest from potential clients and partners.
Potential Negatives
- While the FDA clearance for the CUSA Clarity Ultrasonic Surgical Aspirator System is a positive development, the announcement may raise concerns regarding the company's previous performance and need for new product approvals, indicating potential challenges in maintaining innovation and market competitiveness.
- The focus on cardiac surgery expansion might highlight a strategic dependence on specific medical fields, which could pose risks if market dynamics shift or if there are significant complications associated with cardiac surgeries using the new device.
- The press release lacks information on any post-market surveillance or previous efficacy data, which may lead to skepticism about the safety and performance of the device among healthcare professionals and investors.
FAQ
What is the CUSA Clarity Ultrasonic Surgical Aspirator System?
The CUSA Clarity is a surgical aspirator system designed for debridement in various surgical procedures, including cardiac surgeries.
What recent clearance did Integra LifeSciences receive?
Integra LifeSciences received FDA 510(k) clearance for the CUSA Clarity for specific cardiac surgery indications.
When will Integra showcase the CUSA Clarity?
Integra will showcase the CUSA Clarity at the American Association for Thoracic Surgeons Mitral Valve Conclave on December 11-12, 2025.
What types of surgeries can use the CUSA Clarity system?
The CUSA Clarity is used in cardiac, neurosurgery, orthopedic, plastic, thoracic, laparoscopic, gynecological, and liver transplant surgeries.
Who can I contact for more information about Integra LifeSciences?
You can contact Chris Ward for investor relations or Laurene Isip for media inquiries for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IART Insider Trading Activity
$IART insiders have traded $IART stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IART stock by insiders over the last 6 months:
- JEFFREY A GRAVES purchased 9,000 shares for an estimated $102,150
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IART Hedge Fund Activity
We have seen 108 institutional investors add shares of $IART stock to their portfolio, and 123 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 2,710,262 shares (+58.4%) to their portfolio in Q2 2025, for an estimated $33,254,914
- ALLIANCEBERNSTEIN L.P. removed 2,626,194 shares (-97.0%) from their portfolio in Q2 2025, for an estimated $32,223,400
- WELLINGTON MANAGEMENT GROUP LLP removed 1,442,357 shares (-52.1%) from their portfolio in Q2 2025, for an estimated $17,697,720
- LORD, ABBETT & CO. LLC removed 1,328,701 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $16,303,161
- MORGAN STANLEY removed 876,770 shares (-18.2%) from their portfolio in Q2 2025, for an estimated $10,757,967
- CAPITAL RESEARCH GLOBAL INVESTORS removed 825,742 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,131,854
- DEERFIELD MANAGEMENT COMPANY, L.P. added 794,865 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,752,993
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IART Analyst Ratings
Wall Street analysts have issued reports on $IART in the last several months. We have seen 0 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Sell" rating on 10/31/2025
- JP Morgan issued a "Underweight" rating on 10/31/2025
To track analyst ratings and price targets for $IART, check out Quiver Quantitative's $IART forecast page.
$IART Price Targets
Multiple analysts have issued price targets for $IART recently. We have seen 4 analysts offer price targets for $IART in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Ravi Misra from Truist Securities set a target price of $13.0 on 11/03/2025
- Joanne Wuensch from Citigroup set a target price of $11.0 on 10/31/2025
- Robbie Marcus from JP Morgan set a target price of $13.0 on 10/31/2025
Full Release
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA ® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair.
In addition to cardiac surgery, the CUSA Clarity Ultrasonic Surgical Aspirator System is indicated for use in surgical procedures where fragmentation, emulsification and aspiration of soft and hard (e.g. bone) tissue is desirable, such as neurosurgery, plastic and reconstructive surgery, orthopedic surgery, thoracic surgery, laparoscopic surgery, gynecological surgery, and liver resection and transplant surgery.
“The utilization of CUSA Clarity for cardiac surgery marks the next pivotal expansion of the ultrasonic surgical aspirator system’s breadth of indications,” said Mike McBreen, executive vice president and president of Integra’s Codman Specialty Surgical division. “As one of the leaders in the industry, this milestone strengthens our ability to deliver advanced surgical solutions to support restoring patients’ lives.”
Integra LifeSciences will spotlight the CUSA Clarity Ultrasonic Surgical Aspirator System at the American Association for Thoracic Surgeon Mitral Valve Conclave in New York City on December 11 and 12, 2025.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit
www.integralife.com
.
Investor Relations:
Chris Ward
(609) 772-7736
[email protected]
Media Contact:
Laurene Isip
(609) 208-8121
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2795c2cd-fb23-4998-8dd9-8147f524564c
